<DOC>
	<DOCNO>NCT02106650</DOCNO>
	<brief_summary>This study evaluate effect leucovorin prevent reduce Folotyn-related Grade 3 high oral mucositis .</brief_summary>
	<brief_title>Phase 2 , Single Arm , Open Label Study Folotyn Combination With Oral Leucovorin Prevent Reduce Mucositis Patients With PTCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>Diagnosed relapsed refractory PTCL . At least 18 year age . Recovered toxic effect prior therapy , least 30 day recent cytotoxic therapy . Adequate hematologic , hepatic , renal function define : Absolute neutrophil count ( ANC ) ≥1000/μL . Platelet count ≥100,000/μL . Total bilirubin ≤1.5 mg/dL . AST/SGOT , ALT/SGPT , GGT ≤2.5 × ULN , AST/ALT/GGT ≤5 × ULN document hepatic involvement lymphoma ) . Creatinine ≤1.5 mg/dL calculate creatinine clearance ≥50 mL/min . ECOG ≤2 Active concurrent malignancy . If history prior malignancy , patient diseasefree ≥5 year . Patients prior malignancy less 5 year study entry may still enrol receive treatment result complete resolution cancer currently clinical , radiologic , laboratory evidence active recurrent disease . Congestive heart failure Class III/IV accord New York Heart Association ( NYHA ) Functional Classification . Uncontrolled hypertension . Known , uncontrolled HIVpositive diagnosis . Symptomatic CNS metastasis lesion treatment require . Prophylactic CNS treatment eligible . Active uncontrolled infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment . Had major surgery within 14 day prior enrollment . Used investigational drug , biologics , device within 30 day prior study treatment plan use course study . Had previous exposure Folotyn within 6 month study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed PTCL</keyword>
	<keyword>Refractory PTCL</keyword>
</DOC>